Beyond Pregnancy Registries: Complementary Post-Marketing Approaches
Executive Summary
New techniques cannot replace registries but can address their limitations, stakeholders tell FDA.
You may also be interested in...
Pregnancy Registries Are Insufficient To Assess Drug Safety, US FDA Says
Draft guidance recommends complementary studies to evaluate effects of drug use during pregnancy; FDA may require lactation studies more frequently.
FDA Poised To Require More Rigorous Study Of Drug Use In Pregnancy
With new guidance expected, internal comparison groups, better protocols and potential generic industry involvement are some features that appear likely for the next generation of post-marketing requirements to assess drug safety in pregnancy.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.